Thermo Fisher Scientific Human TRPC6 Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to 14 amino acids near the carboxy terminus of human TRPC6.
PEP-0392 can be used as a blocking peptide with polyclonal antibody PA5-20256.

Target Information

Trpc6 forms a receptor-activated calcium channel in the cell membrane. The Trpc6 channel is activated by diacylglycerol and is thought to be under the control of a phosphatidylinositol second messenger system. Activation of the Trpc6 channel occurs independently of protein kinase C and is not triggered by low levels of intracellular calcium.

Defects in the Trpc6 gene are a cause of focal segmental glomerulosclerosis 2 (FSGS2). Trpc6 is a member of the mammalian transient receptor potential (TRP) superfamily, which can be divided into three major families including the “canonical TRP” (TRPC) family. The seven members of this family share activation through PLC-coupled receptors and are suggested to be components of receptor-regulated cation channels in different cell types.

Members of the TRPC3/6/7 subfamily can be activated by diacylglycerol (DAG) analogs, suggesting a possible mechanism of activation of these channels by PLC-coupled receptors. When expressed in transfected cells, Trpc6 acts as a non-selective, store-independent, receptor-activated cation channel. Trpc6 is activated by DAG in a PKC-independent manner and is insensitive to IP3 activation.

There is increasing evidence that Trpc6 encodes endogenous DAG-activated receptor-operated cation channels in vivo. Diseases associated with TRPC6 include Glomerulosclerosis, Focal Segmental, 2 and Focal Segmental Glomerulosclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.